Benzinga | Nov 5, 2021 10:55AM EDT

SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $850

SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $798 to $850.